Evidence map›Paper›PMID 28258298›Full record

ArticleBasic research in cardiology2017

Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function.

Soeren E Pischke, A Gustavsen, H L Orrem, K H Egge, F Courivaud, H Fontenelle, A Despont, A K Bongoni, R Rieben, T I Tønnessen and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Basic research in cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Targeting GαBasic research in cardiology · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Immunomodulatory Proteins in Tick Saliva From a Structural Perspective.Frontiers in cellular and infection microbiology · 2021
    Review
  12. Review
  13. MiR-101a loaded extracellular nanovesicles as bioactive carriers for cardiac repair.Nanomedicine : nanotechnology, biology, and medicine · 2020
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 4 countries.

Soeren E PischkeDepartment of Immunology, Oslo University Hospital, Rikshospitalet, P.b. 4950 Nydalen, 0424, Oslo, Norway. s.e.pischke@medisin.uio.no.ORCID 0000-0003-2543-3251
A GustavsenDepartment of Immunology, Oslo University Hospital, Rikshospitalet, P.b. 4950 Nydalen, 0424, Oslo, Norway.
H L OrremDepartment of Immunology, Oslo University Hospital, Rikshospitalet, P.b. 4950 Nydalen, 0424, Oslo, Norway.
K H EggeDepartment of Immunology, Oslo University Hospital, Rikshospitalet, P.b. 4950 Nydalen, 0424, Oslo, Norway.
F CourivaudIntervention Centre, Oslo University Hospital, Oslo, Norway.
H FontenelleIntervention Centre, Oslo University Hospital, Oslo, Norway.
A DespontDepartment of Clinical Research, University of Bern, Bern, Switzerland.
A K BongoniImmunology Research Centre, St. Vincent's Hospital, Melbourne, VIC, Australia.
R RiebenDepartment of Clinical Research, University of Bern, Bern, Switzerland.
T I TønnessenDivision of Emergencies and Critical Care, Department of Anaesthesiology, Oslo University Hospital, Oslo, Norway.
M A NunnAkari Therapeutics Plc, London, UK.
H ScottDepartment of Pathology, Oslo University Hospital, University of Oslo, Oslo, Norway.
H SkulstadDepartment of Cardiology, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway.
A Barratt-DueDepartment of Immunology, Oslo University Hospital, Rikshospitalet, P.b. 4950 Nydalen, 0424, Oslo, Norway.
T E MollnesDepartment of Immunology, Oslo University Hospital, Rikshospitalet, P.b. 4950 Nydalen, 0424, Oslo, Norway.
Oslo University Hospital · NOUniversity of Bern · CHAkari Therapeutics (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of complement factor 5 (C5) reduced myocardial infarction in animal studies, while no benefit was found in clinical studies. Due to lack of cross-reactivity of clinically used C5 antibodies, different inhibitors were used in animal and clinical studies. Coversin (Ornithodoros moubata complement inhibitor, OmCI) blocks C5 cleavage and binds leukotriene B4 in humans and pigs. We hypothesized that inhibition of C5 before reperfusion will decrease infarct size and improve ventricular function in a porcine model of myocardial infarction. In pigs (Sus scrofa), the left anterior descending coronary artery was occluded (40 min) and reperfused (240 min). Coversin or placebo was infused 20 min after occlusion and throughout reperfusion in 16 blindly randomized pigs. Coversin significantly reduced myocardial infarction in the area at risk by 39% (p = 0.03, triphenyl tetrazolium chloride staining) and by 19% (p = 0.02) using magnetic resonance imaging. The methods correlated significantly (R = 0.92, p < 0.01). Tissue Doppler echocardiography showed increased systolic displacement (31%, p < 0.01) and increased systolic velocity (29%, p = 0.01) in coversin treated pigs. Interleukin-1β in myocardial microdialysis fluid was significantly reduced (31%, p < 0.05) and tissue E-selectin expression was significantly reduced (p = 0.01) in the non-infarcted area at risk by coversin treatment. Coversin ablated plasma C5 activation throughout the reperfusion period and decreased myocardial C5b-9 deposition, while neither plasma nor myocardial LTB4 were significantly reduced. Coversin substantially reduced the size of infarction, improved ventricular function, and attenuated interleukin-1β and E-selectin in this porcine model by inhibiting C5. We conclude that inhibition of C5 in myocardial infarction should be reconsidered.

Indexed as

AnimalsArthropod ProteinsCarrier ProteinsComplement C5Disease Models, AnimalEchocardiographyFluorescent Antibody TechniqueMagnetic Resonance ImagingMyocardial InfarctionRandom AllocationSus scrofaArthropod ProteinsCarrier ProteinsComplement C5OmCI protein, tickC5ComplementContractilityIschemia/reperfusionLTB4Myocardial infarction

Identifiers

PMID28258298
PMCPMC5336537
OpenAlexW2594918030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.